Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.
Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.
Enhancing Vitreoretinal Surgery Training via Virtual Reality
At the annual meeting of the Canadian Ophthalmological Society, the winner of an event modeled after the television program Shark Tank involved a project for a virtual reality (VR) simulator designed to boost retinal surgery training.
As reported by Ophthalmology Times®, vitreoretinal surgery training is not commonly provided during ophthalmology residency, with mastery requiring several years of preparation. In pitching the VR simulator during the event, the presenter noted that it could be leveraged to administer proficiency-based tests to ensure trainees are ready to perform procedures on patients.
The proposed VR simulator will be developed jointly by an engineering and ophthalmology team through iterative feedback and would be compatible with commercially available headsets and instruments. It is also set to be involved in a 2-phase study.
Maternal Diabetes Linked With Eye Issues in Offspring
As reported by Modern Retina™, findings of a long-term study published in Diabetologia found that children of mothers with diabetes during pregnancy were at a 39% increased risk of developing high refractive error from birth until age 25.
Evaluating data from approximately 2.4 million people born in Denmark between 1977 and 2016, increased risks in children with prenatal maternal exposure to diabetes were observed for hypermetropia, myopia, and astigmatism. Moreover, incidence was found to be more likely in children of mothers with diabetes who experienced diabetic complications vs those with mothers who had the condition but did not have complications.
By type of diabetes, risk for refractive error was found to be 32% higher in children who had mothers with type 1 diabetes and 68% in those who had mothers with type 2 diabetes, compared with unexposed offspring. Researchers concluded that early identification and intervention could provide a long-term positive impact on young children.
Collision-Warning Device Effective for Visually Impaired Patients
An electronic mobility aid designed to reduce collisions was found in a real-world study to decrease the rate of collisions by 37% in blind patients and those with severely impaired vision. Findings were reported by Modern Retina™.
Patients of the double-masked, randomized clinical trial were assessed via contact with obstacles detected during daily walks over the course of 4 weeks. Utilizing a video camera and microcomputer, the device was enclosed in a slingback bag, which switched itself randomly from active mode (intervention), where users were alerted to the potential for a collision via 2 vibrotactile wristbands, and silent mode, the control condition that detects the threat of collisions without providing warnings.
Participants whose device was set in active mode were also shown to have a significantly lower median number of contacts than those of the control group (9.3 vs 13.8; P < .001).
Hospital Stays and Probable Dementia as Predictors of Relocation to Long-Term Care Facilities
October 22nd 2024This article explores late-life relocations in patients with dementia, hospital stays, and their implications for health care policy, geriatric care, and future research priorities.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More